Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 8;14:1979. doi: 10.1038/s41467-023-37712-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a Histone modifications in CALM-AF10 leukemia cells after treatment with MOZ/MORF KAT (WM1119) and DOT1L KMT (EPZ-5676) inhibitors. WB of the P31/FUJ cells treated with 10 µM of WM1119 or EPZ-5676 for 6 days using antibodies specific to each histone modification. b Leukemia cell proliferation in the presence of WM1119 and EPZ-5676. P31/FUJ cell proliferation in the presence of 10 µM WM1119 or EPZ-5676 was monitored for 21 days along with the vehicle control (DMSO). c Histone modifications in HEK293T cells after treatment with WM1119. WB of the HEK293T cells treated with 10 µM of WM1119 for 24 h using antibodies specific to each histone modification. d HOXA gene expression in HEK293T cells after treatment with WM1119 and EPZ-5676. RT-qPCR of the HEK293T cells treated with 10 μM of WM1119 (W), EPZ-5676 (E), or DMSO control (D) for 5 days (mean ± SD of technical replicates, n = 3). Multiple comparisons were performed using a one-way ANOVA. e Localization of ENL, MOZ, and DOT1L after treatment with WM1119 and EPZ-5676. ChIP-qPCR of HEK293T cells treated with 10 µM of WM1119 or EPZ-5676 for 5 days was performed as in Fig. 2d (mean ± SD of technical replicates, n = 3). Multiple comparisons were made using a two-way ANOVA. f Effects of WM1119 on protein interactions in ENL. IP-WB of the chromatin fraction of HEK293T cells stably expressing various FLAG-tagged ENL constructs with (W: WM1119) or without (D: DMSO control) the treatment with WM1119 at 10 µM for 5 days was performed. The co-precipitates were analyzed using anti-FLAG and MOZ antibodies. The relative band intensity was quantified using the Image J software. g Localization of CALM-AF10 after treatment with WM1119. HEK293T cells stably expressing FLAG-tagged CALM-AF10 (fCALM-AF10) were treated with 10 µM WM1119 (W) or the DMSO control (D) for 5 days and subjected to ChIP-qPCR analysis as in Fig. 2d (mean ± SD of technical replicates, n = 3). Multiple comparisons were performed using a two-way ANOVA. Source data are provided as a Source Data file.